IMWG consensus on maintenance therapy in multiple myeloma
Top Cited Papers
- 29 March 2012
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 119 (13), 3003-3015
- https://doi.org/10.1182/blood-2011-11-374249
Abstract
Maintaining results of successful induction therapy is an important goal in multiple myeloma. Here, members of the International Myeloma Working Group review the relevant data. Thalidomide maintenance therapy after autologous stem cell transplantation improved the quality of response and increased progression-free survival (PFS) significantly in all 6 studies and overall survival (OS) in 3 of them. In elderly patients, 2 trials showed a significant prolongation of PFS, but no improvement in OS. A meta-analysis revealed a significant risk reduction for PFS/event-free survival and death. The role of thalidomide maintenance after melphalan, prednisone, and thalidomide is not well established. Two trials with lenalidomide maintenance treatment after autologous stem cell transplantation and one study after conventional melphalan, prednisone, and lenalidomide induction therapy showed a significant risk reduction for PFS and an increase in OS in one of the transplant trials. Maintenance therapy with single-agent bortezomib or in combination with thalidomide or prednisone has been studied. One trial revealed a significantly increased OS with a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction and thalidomide maintenance treatment. Maintenance treatment can be associated with significant side effects, and none of the drugs evaluated is approved for maintenance therapy. Treatment decisions for individual patients must balance potential benefits and risks carefully, as a widely agreed-on standard is not established.This publication has 47 references indexed in Scilit:
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisBlood, 2012
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood, 2011
- A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantLeukemia & Lymphoma, 2011
- Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myelomaHaematologica, 2010
- Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical SciencesJournal of Clinical Oncology, 2010
- The molecular characterization and clinical management of multiple myeloma in the post-genome eraLeukemia, 2009
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBlood, 2008
- Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma NetworkJournal of Clinical Oncology, 2007
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- INTERFERON THERAPY IN MYELOMATOSISThe Lancet, 1979